AKTX - Akari Therapeutics, Plc
| Previous Close | 1.9800 |
| Open | 1.9298 |
| Bid | 0.39 x 1800 |
| Ask | 2.85 x 1100 |
| Day's Range | 1.8200 - 1.9700 |
| 52 Week Range | 1.5600 - 3.5590 |
| Volume | 4,806 |
| Avg. Volume | 24,027 |
| Market Cap | 28.769M |
| Beta (3Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.93 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- Simply Wall St.•27 days ago
What You Must Know About Akari Therapeutics, Plc’s (NASDAQ:AKTX) Beta Value
If you own shares in Akari Therapeutics, Plc (NASDAQ:AKTX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- GlobeNewswire•2 months ago
Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced recent developments and supporting data which underscore the differentiation of Coversin. “We are encouraged by new data that demonstrates the potential for improved patient comfort and ease of use. Alongside this focus on patient convenience we continue to develop Coversin as a differentiated treatment by means of its combined complement C5 and LTB4 inhibitory activity with early data readouts of our bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) trials expected in first quarter 2019,” said Clive Richardson, Interim Chief Executive Officer of Akari Therapeutics.
- GlobeNewswire•2 months ago
Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and or leukotriene systems are implicated, today announced that PASylated Coversin data will be presented at the 2nd Annual 2018 Complement-Based Drug Development Summit in Boston, Mass. during an oral presentation by Andrew Luster, M.D., Ph.D., Chief, Division of Rheumatology, Allergy and Immunology & Director, Center for Immunology and Inflammatory Diseases Massachusetts General Hospital. Akari currently has two clinical programs open in bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) where both C5 and LTB4 are believed to be implicated.
- GlobeNewswire•3 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Intersect ENT, Akari Therapeutics, Ampio Pharmaceuticals, Virtusa, Umpqua, and Hamilton Lane — New Research Emphasizes Economic Growth
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Simply Wall St.•8 months ago
How Do Analysts See Akari Therapeutics Plc (NASDAQ:AKTX) Performing In The Years Ahead?
Akari Therapeutics Plc’s (NASDAQ:AKTX) latest earnings announcement in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Below, I’veRead More...
- Simply Wall St.•8 months ago
Should You Buy Akari Therapeutics Plc (NASDAQ:AKTX) Now?
Akari Therapeutics Plc (NASDAQ:AKTX), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the highs ofRead More...
- ACCESSWIRE•9 months ago
Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases
Stock Monitor: Akari Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on Tetraphase Pharma, Inc. (NASDAQ: TTPH ...
- Thomson Reuters StreetEvents•10 months ago
Edited Transcript of AKTX earnings conference call or presentation 21-Mar-18 12:30pm GMT
Q4 2017 Akari Therapeutics PLC Earnings Call
